Pesquisar um ensaio clínico
Outras opções de pesquisa
125 Resultado(s)
Ensaio em fase de recrutamento = 
; Ensaio a decorrer = 
; Financiado por um membro do IRDiRC = 
; Membro de uma ERN = 
Ensaio (s) clínico (s) nacional (is)
ALEMANHA
Sachsen
LEIPZIG
RELAZA2 (TUD-RELA02-048): Treatment of patients with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) with an impending hematological relapse with Azacitidin (Phase II)
Universitätsklinikum Leipzig AöR
Klinik und Poliklinik für Hämatologie, Zelltherapie und Hämostaseologie
FINLANDIA
Finland
HELSINKI
Clinical Phase III Trial to Compare Treosulfan-based Conditioning Therapy With Busulfan-based Reduced-intensity Conditioning (RIC) Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients With AML or MDS Considered Ineligible to Standard Conditioning Regimens - FI
HUS - Helsinki University Hospital
Comprehensive Cancer Center
REINO UNIDO
Avon
BRISTOL
A Phase 2, Randomized, Biomarker-driven, Clinical Study in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with an Exploratory Arm in Patients with Newly Diagnosed High-Risk AML -GB
Bristol Royal Infirmary
University Hospitals Bristol NHS Foundation Trust HQ
ALEMANHA
Baden-Württemberg
FREIBURG
HaploMUD: Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia With Identical GVHD Prophylaxis - A Randomized Prospective European Trial - DE
Universitätsklinikum Freiburg
Klinik für Innere Medizin I - Hämatologie, Onkologie und Stammzelltransplantation
ALEMANHA
Baden-Württemberg
HEIDELBERG
INFORM2 NivEnt: exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies
Deutsches Krebsforschungszentrum
Klinische Kooperationseinheit Pädiatrische Onkologie
ALEMANHA
Baden-Württemberg
TÜBINGEN
CD3/CD19 Haplo (E410/2007): Multicenter phase II study of Haploidentical Hematopoietic Cell Transplantation with CD3/CD19 depleted Grafts after a reduced intensity conditioning regimen for adult Patients with Acute Leukemia
Department für Innere Medizin - Medizinische Universitätsklinik Tübingen
Innere Medizin II - Onkologie, Hämatologie, Klinische Immunologie, Rheumatologie und Pulmologie
ALEMANHA
Baden-Württemberg
ULM
An open phase I/IIa trial to investigate the maximum tolerated dose, safety, pharmacokinetics, and efficacy of intravenous BI 6727 as monotherapy or in combination with subcutaneous Cytarabine in patients with Acute Myeloid Leukemia (AML) - DE
Universitätsklinikum Ulm am Oberen Eselsberg
Klinik für Innere Medizin III
ALEMANHA
Baden-Württemberg
ULM
CLASSIC I: A Phase III Randomized, Double-blind, Controlled Study Comparing Clofarabine and Cytarabine Versus Cytarabine Alone in Adult Patients 55 Years and Older With Acute Myelogenous Leukemia (AML) Who Have Relapsed or Are Refractory After Receiving up to Two Prior Induction Regimens
Universitätsklinikum Ulm am Oberen Eselsberg
Klinik für Innere Medizin III
ALEMANHA
Baden-Württemberg
ULM
AMLSG 11-08: Open-label, multicenter phase Ib/IIa study for the evaluation of Dasatinib following induction and consolidation therapy as well as in maintenance therapy in patients with newly diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)
Universitätsklinikum Ulm am Oberen Eselsberg
Klinik für Innere Medizin III
ALEMANHA
Baden-Württemberg
ULM
AMLSG 19-13: Dose Finding Run-in Phase I Followed by a Phase III, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of Crenolanib in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations - DE
Universitätsklinikum Ulm am Oberen Eselsberg
Klinik für Innere Medizin III
ALEMANHA
Bayern
MÜNCHEN
Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation
LMU Klinikum der Universität München - Campus Großhadern
LMU Klinikum
ALEMANHA
Bayern
MÜNCHEN
AML-CG 2008: A Randomized, risk and age adapted comparison of the dose-dense regimen S-HAM (sequential high dose cytosine arabinoside and mitoxantrone) versus standard double induction for initial Chemotherapy of adult patients with Acute Myeloid Leukemia (Phase III)
LMU Klinikum der Universität München - Campus Großhadern
Medizinische Klinik und Poliklinik III
ALEMANHA
Bayern
REGENSBURG
INFORM2 NivEnt: exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies
Universitätsklinikum Regensburg
Abteilung für Pädiatrische Hämatologie, Onkologie und Stammzelltransplantation
ALEMANHA
Berlin
ADDRESS: NOT PROVIDED - DE
CLBH589H2101 - A phase I/b, open-label, multicenter, dose-escalation study of oral panobinostat (LBH589) administered with 5-azacitidine (Vidaza®) in adult patients with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) - DE
Institution: Information not provided - DE
ALEMANHA
Berlin
ADDRESS: NOT PROVIDED - DE
A Phase 1 Study of AMG 330 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia -DE-
Institution: Information not provided - DE
ALEMANHA
Berlin
ADDRESS: NOT PROVIDED - DE
AZA-AML-004: A randomized, multicenter, open-label, Phase 2 study with a safety run-in part to evaluate safety, pharmacodynamics and efficacy of azacitidine compared to no anticancer treatment in children and young adults with acute myeloid leukemia in molecular relapse after first complete remission -DE-
Institution: Information not provided - DE
ALEMANHA
Berlin
ADDRESS: NOT PROVIDED - DE
A Phase 1/2 Study of Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Subjects With Acute Myelogenous Leukemia Who Are Greater Than or Equal to 60 Years of Age and Who Are Not Eligible for Standard Anthracycline-Based Induction Therapy -DE-
Institution: Information not provided - DE
ALEMANHA
Berlin
ADDRESS: NOT PROVIDED - DE
A Phase 1b Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine in Treatment-Naive Subjects With Acute Myelogenous Leukemia Who Are = 65 Years of Age and Who Are Not Eligible for Standard Induction Therapy -DE-
Institution: Information not provided - DE
ALEMANHA
Hamburg
HAMBURG
HaploMUD: Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia With Identical GVHD Prophylaxis - A Randomized Prospective European Trial - DE
UKE - Universitätsklinikum Hamburg-Eppendorf
Interdisziplinäre Klinik und Poliklinik für Stammzelltransplantation
ALEMANHA
Hessen
FRANKFURT AM MAIN
A Prospective Phase I/II Study to Investigate the Feasibility, Safety and Efficacy of IL-15 Activated Cytokine Induced Killer (CIK) Cells in Relapsing Patients With Acute Leukemia or Myelodysplastic Syndromes After Allogeneic SCT - DE
Klinikum der Johann Wolfgang Goethe-Universität Frankfurt
Schwerpunkt Stammzelltransplantation und Immunologie
ALEMANHA
Hessen
FRANKFURT AM MAIN
PANOBEST: Phase I/II study with oral panobinostat maintenance therapy following allogeneic stem cell transplantation in patients with high risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
Klinikum der Johann Wolfgang Goethe-Universität Frankfurt
Medizinische Klinik II - Hämatologie, Onkologie, Hämostaseologie, Rheumatologie, Infektiologie
ALEMANHA
Hessen
MARBURG
SORMAIN: A double-blind, placebo-controlled, randomised, multicentre phase II trial to assess the efficacy and safety of Sorafenib-maintenance therapy in Flt3-ITD positive Acute Myeloid Leukemia in complete haematological remission after allogenic stem cell transplantation
Universitätsklinikum Gießen und Marburg GmbH, Standort Marburg
Klinik für Innere Medizin - Schwerpunkt Hämatologie, Onkologie und Immunologie
ALEMANHA
Niedersachsen
HANNOVER
HaploMUD: Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia With Identical GVHD Prophylaxis - A Randomized Prospective European Trial - DE
Medizinische Hochschule Hannover
Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation
ALEMANHA
Niedersachsen
HANNOVER
AML SCT-BFM 2007 : Phase III multicenter therapy study: Allogenic Stem Cell Transplantation for children, adolescents and young adults with relapsed or refractory Acute myeloid Leukemia (AML) - DE
Medizinische Hochschule Hannover
Klinik für Pädiatrische Hämatologie und Onkologie
ALEMANHA
Nordrhein-Westfalen
DÜSSELDORF
Phase-II trial to assess the efficacy and toxicity of 5-Azacitidine in addition to standard donor lymphocyte for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome relapsing after allogeneic stem cell transplantation
Universitätsklinikum Düsseldorf
Klinik für Hämatologie, Onkologie und Klinische Immunologie
ALEMANHA
Nordrhein-Westfalen
DÜSSELDORF
AZALENA: Phase-II Trial to Assess the Efficacy and Safety of Lenalidomide in Addition to 5-Azacitidine and Donor Lymphocyte Infusions (DLI) for the Treatment of Patients With MDS, CMML or AML Who Relapse After Allogeneic Stem Cell Transplantation - DE
Universitätsklinikum Düsseldorf
Klinik für Hämatologie, Onkologie und Klinische Immunologie
ALEMANHA
Nordrhein-Westfalen
DÜSSELDORF
HaploMUD: Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia With Identical GVHD Prophylaxis - A Randomized Prospective European Trial - DE
Universitätsklinikum Düsseldorf
Klinik für Hämatologie, Onkologie und Klinische Immunologie
ALEMANHA
Nordrhein-Westfalen
ESSEN
INFORM2 NivEnt: exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies
Universitätsklinikum Essen
Klinik für Kinderheilkunde III - Abteilung für pädiatrische Hämatologie und Onkologie
ALEMANHA
Nordrhein-Westfalen
ESSEN
HaploMUD: Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia With Identical GVHD Prophylaxis - A Randomized Prospective European Trial - DE
Universitätsklinikum Essen
Klinik für Knochenmarktransplantation
ALEMANHA
Nordrhein-Westfalen
MÜNSTER
HaploMUD: Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia With Identical GVHD Prophylaxis - A Randomized Prospective European Trial - DE
Universitätsklinikum Münster
Medizinische Klinik und Poliklinik A
ALEMANHA
Sachsen
LEIPZIG
BERGAMO: A Phase II Study Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes Failing Standard of Care Therapy -DE
Universitätsklinikum Leipzig AöR
Klinik und Poliklinik für Hämatologie, Zelltherapie und Hämostaseologie
ALEMANHA
Sachsen-Anhalt
MAGDEBURG
CLDE225X2203: A Phase II multicenter, open label, randomized study to assess safety and efficacy of two different schedules of oral LDE225 in adult patients with relapsed / refractory or untreated elderly patients with Acute Leukemia - DE
Universitätsklinikum Magdeburg A.ö.R
Universitätsklinik für Hämatologie und Onkologie
ALEMANHA
Thüringen
JENA
Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation
Universitätsklinikum Jena
Klinik für Innere Medizin II - Abteilung Hämatologie und Internistische Onkologie
AUSTRIA
STEIERMARK
GRAZ
HaploMUD: Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia With Identical GVHD Prophylaxis - A Randomized Prospective European Trial - AT
Medizinische Universität Graz
Klinische Abteilung für Hämatologie
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
AGILE: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination With Azacitidine in Subjects > 18 Years of Age With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML) - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
ARMADA 2000: Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination with High Dose Cytarabine and Mitoxantrone (CHAM) Compared to High Dose Cytarabine and Mitoxantrone (HAM) in Older Patients (>=60 years) with Relapsed/Refractory Acute Myeloid Leukemia (AML) - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
Randomized Clinical Study of Haplo-Identical Donors Versus Unrelated Donors in Hematopoietic Stem Cell Transplant Patients With Acute Myeloid Leukemia - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
WIEN
AML SCT-BFM 2007 : Phase III multicenter therapy study: Allogenic Stem Cell Transplantation for children, adolescents and young adults with relapsed or refractory Acute myeloid Leukemia (AML) - AT
St. Anna Kinderspital
Zentrum für Kinder- und Jugendheilkunde
AUSTRIA
WIEN
WIEN
Clinical Phase II Trial to Describe the Safety and Efficacy of Treosulfan-based Conditioning Therapy Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Paediatric Patients With Haematological Malignancies - AT
St. Anna Kinderspital
Zentrum für Kinder- und Jugendheilkunde
BELGICA
ANTWERPEN
ANTWERPEN
A Randomized, Double Blind Phase 1b/2 Study Of Pf 04449913 (Glasdegib) In Combination With Azacitidine In Patients With Previously Untreated Intermediate 2 Or High Risk Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Blasts And Multi Lineage Dysplasia, Or Chronic Myelomonocytic Leukemia - BE
Ziekenhuis Netwerk Antwerpen (ZNA) - Campus Stuivenberg
Hematologie (Bloedziekten)
BELGICA
ANTWERPEN
ANTWERPEN
HOVON 116 AML: A phase I/II feasibility study of panoninostat alone and the combination of panobinostat and decitabine prior to donor lymphocyte infusion in recipients of allogeneic stem cell transplantation with poor and very poor risk AML- BE
Ziekenhuis Netwerk Antwerpen (ZNA) - Campus Stuivenberg
Hematologie (Bloedziekten)
BELGICA
ANTWERPEN
ANTWERPEN-EDEGEM
Therapeutic efficacy of Wilms tumor gene (WT1) mRNA-electroporated autologous dendritic cell vaccination in patients with myeloid malignancies and multiple myeloma: a phase II trial
University Hospital of Antwerp - UZA
Department of Hematology
BELGICA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Sequential administration of 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation.
Cliniques universitaires Saint-Luc - UCLouvain
Cliniques Universitaires Saint-Luc
BELGICA
BRABANT WALLON
MONT-SAINT-GUIBERT
BELGICA
LIEGE
LIEGE
Co-transplantation of Mesenchymal Stem Cells and HLA-mismatched Allogeneic Hematopoietic Cells After Nonmyeloablative Conditioning: a Phase II Randomized Double-blind Study
CHU Sart Tilman - Liège
Department of Hematology / Hématologie clinique
BELGICA
NAMUR
YVOIR
Sequential administration of 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation.
Cliniques Universitaires UCL de Mont-Godinne
CHU Dinant-Godinne UCL Namur
BELGICA
OOST-VLAANDEREN
GENT
A Phase 1/2, Multicenter, Dose-Escalating Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy Of Quizartinib Administered in Combination with Re-Induction Chemotherapy, and as a Single-Agent Maintenance Therapy, in Pediatric Relapsed/Refractory AML Subjects Aged 1 Month to <18 Years (and Young Adults Aged up to 21 Years) with FLT3-ITD mutations - BE
Kinderziekenhuis Prinses Elisabeth- UZ Gent
Pediatric Hematology-Oncology and Stem Cell Transplantation/Afdeling Hemato-oncologie en stamceltransplantatie kinderen
BELGICA
VLAAMS BRABANT
LEUVEN
HOVON 132 AML/SAKK 30/13: Randomized study with a run-in dose-selection phase to assess the added value of lenalidomide in combination with standard remission-induction chemotherapy and post-remission treatment in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or high risk myelodysplasia (MDS) (IPSS-R risk score > 4.5) - BE
UZ Leuven - Campus Gasthuisberg
Department of Hematology
BELGICA
VLAAMS BRABANT
LEUVEN
HOVON 102 AML / SAKK 30/09: Randomized study with a run-in feasibility phase to assess the added value of Clofarabine in combination with standard remission-induction chemotherapy in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or myelodysplasia (MDS) (RAEB with IPSS = 1.5) (phase II-III) - BE
UZ Leuven - Campus Gasthuisberg
Department of Hematology
ESPANHA
Andalucía
GRANADA
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML) - ES
Hospital Universitario Virgen de las Nieves
Servicio de Hematología
ESPANHA
Asturias
OVIEDO
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML) - ES
Hospital Universitario Central de Asturias
Servicio de Hematología y Hemoterapia
ESPANHA
Cantabria
SANTANDER
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML) - ES
Hospital Universitario Marqués de Valdecilla
ESPANHA
Castilla - León
SALAMANCA
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML) - ES
Hospital Clínico Universitario de Salamanca
Servicio de Hematología
ESPANHA
Cataluña
L'HOSPITALET DE LLOBREGAT
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML) - ES
ICO Hospitalet - Hospital Duran i Reynals
ICO Hospitalet
ESPANHA
Comunidad Valenciana
VALENCIA
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML) - ES
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia
ESPANHA
Extremadura
CÁCERES
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML) - ES
Hospital San Pedro de Alcántara
Servicio de Hematología y Hemoterapia
ESPANHA
Madrid
ADDRESS: NOT PROVIDED - ES
AGILE: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination With Azacitidine in Subjects >= 18 Years of Age With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation - ES
Institution: Information not provided - ES
ESPANHA
Madrid
ADDRESS: NOT PROVIDED - ES
ARMADA 2000: Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination with High Dose Cytarabine and Mitoxantrone (CHAM) Compared to High Dose Cytarabine and Mitoxantrone (HAM) in Older Patients (>=60 years) with Relapsed/Refractory Acute Myeloid Leukemia (AML) - ES
Institution: Information not provided - ES
ESPANHA
Madrid
MADRID
Clinical trial phase I/II, single-center, historical control, to evaluate the effectiveness of donor IL-15-stimulated NK cells post transplant infusion, in acute leukemia patients with poor prognosis and haploidentical unmanipulated transplant - ES
Hospital General Universitario Gregorio Marañón
Servicio de Hematología y Hemoterapia
ESPANHA
Madrid
MADRID
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML) - ES
Hospital General Universitario Gregorio Marañón
Servicio de Hematología y Hemoterapia
ESPANHA
Madrid
MADRID
A Phase 1/2, Multicenter, Dose-Escalating Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy Of Quizartinib Administered in Combination with Re-Induction Chemotherapy, and as a Single-Agent Maintenance Therapy, in Pediatric Relapsed/Refractory AML Subjects Aged 1 Month to <18 Years [...] with FLT3-ITD mutations - ES
Hospital Infantil Universitario Niño Jesús
Servicio de Oncohematología
ESPANHA
Madrid
MADRID
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML) - ES
Hospital Universitario 12 de Octubre
Servicio de Hematología y Hemoterapia
ESPANHA
Madrid
MADRID
Natural Killer cell infusion as consolidation therapy in children and adolescents with acute myelogenous leukemia (Phase II) - ES
Hospital Universitario La Paz
Servicio de Hemato-oncología pediátrica
ESPANHA
Madrid
MADRID
A Phase 1/2, Multicenter, Dose-Escalating Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy Of Quizartinib Administered in Combination with Re-Induction Chemotherapy, and as a Single-Agent Maintenance Therapy, in Pediatric Relapsed/Refractory AML Subjects Aged 1 Month to <18 Years [...] with FLT3-ITD mutations - ES
Hospital Universitario La Paz
Servicio de Hemato-oncología pediátrica
ESPANHA
Navarra
PAMPLONA
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML) - ES
Clínica Universidad de Navarra
Servicio de Hematología y Hemoterapia
ESTADOS UNIDOS
Alabama
BIRMINGHAM
A Randomized, Double-blind Phase 1b/2 Study Of Pf-04449913 (Glasdegib) In Combination With Azacitidine In Patients With Previously Untreated Intermediate-2 Or High-risk Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Blasts And Multi-lineage Dysplasia, Or Chronic Myelomonocytic Leukemia - US
University of Alabama at Birmingham
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
A Phase 1/2, Multicenter, Dose-Escalating Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy Of Quizartinib Administered in Combination with Re-Induction Chemotherapy, and as a Single-Agent Maintenance Therapy, in Pediatric Relapsed/Refractory AML Subjects Aged 1 Month to <18 Years (and Young Adults Aged up to 21 Years) with FLT3-ITD mutations - FR
Institution: Information not provided - US
FRANCA
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
A phase I/II, open-label, dose-escalating study to evaluate the safety, tolerability and pharmacokinetics of oral midostaurin and to evaluate the preliminary clinical and pharmacodynamic response in pediatric patients with relapsed or refractory acute leukemia - FR
Institution: Information not provided - FR
FRANCA
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
A Phase I, Multicenter, Open-label Study of Oral LGH447 in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome-FR
Institution: Information not provided - FR
FRANCA
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
A Phase 1b Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine in Treatment-Naive Subjects With Acute Myelogenous Leukemia Who Are = 65 Years of Age and Who Are Not Eligible for Standard Induction Therapy - FR
Institution: Information not provided - FR
FRANCA
AUVERGNE-RHONE-ALPES
LYON
FRANCA
ILE-DE-FRANCE
LE CHESNAY
PONATINIB-AML : A Phase I-II Study to Assess Safety and Efficacy of the Combination of Ponatinib With High or Intermediate-Dose Cytarabine as Consolidation Therapy for Patients With Intermediate-Risk Cytogenetic FLT3-ITD AML iIn First Complete Remission
CH de Versailles - Hôpital André Mignot
Service d'Hématologie - Oncologie
FRANCA
ILE-DE-FRANCE
LE CHESNAY
MYLOfrance 4 (ALFA1401) : Gemtuzumab Ozogamicin + Cytarabine vs Idarubicin + Cytarabine in Elderly Patients With AML (Phase II-III)
CH de Versailles - Hôpital André Mignot
Service d'Hématologie - Oncologie
FRANCA
ILE-DE-FRANCE
PARIS
TBF-Cord : Reduced Toxicity Conditioning Prior to Unrelated Cord Cell Transplantation for High Risk Myeloid Malignancies (Phase II)
CHU Paris Est - Hôpital Saint-Antoine
Service d'hématologie
FRANCA
ILE-DE-FRANCE
PARIS
SET-HAPLO : Sequential Chemotherapy Prior to Reduced Intensity Conditioning : Interventional Study in Haploidentical Hematopoietic Stem Cells Transplantation for Patients With Refractory Acute Myeloid Leukemia
CHU Paris Est - Hôpital Saint-Antoine
Service d'hématologie
FRANCA
ILE-DE-FRANCE
PARIS
A Phase 1/2, Multicenter, Dose-Escalating Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy Of Quizartinib Administered in Combination with Re-Induction Chemotherapy, and as a Single-Agent Maintenance Therapy, in Pediatric Relapsed/Refractory AML Subjects Aged 1 Month to <18 Years (and Young Adults Aged up to 21 Years) with FLT3-ITD mutations - FR
CHU Paris Est - Hôpital d'Enfants Armand-Trousseau
Service d'Hématologie - Oncologie pédiatrique
FRANCA
ILE-DE-FRANCE
PARIS
A Phase II Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q
CHU Paris-GH St-Louis Lariboisière F.Widal - Hôpital Saint-Louis
Groupe Francophone des Myélodysplasies (GFM)
FRANCA
ILE-DE-FRANCE
PARIS
A phase II study of the efficacy and safety of lenalidomide combined to azacitidine in intermediate-2 or high risk MDS AND AML with del 5q (GFM-Aza-Rev-09)
CHU Paris-GH St-Louis Lariboisière F.Widal - Hôpital Saint-Louis
Groupe Francophone des Myélodysplasies (GFM)
FRANCA
ILE-DE-FRANCE
PARIS
BERGAMO: A Phase II Study Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes Failing Standard of Care Therapy - FR
CHU Paris-GH St-Louis Lariboisière F.Widal - Hôpital Saint-Louis
Service d'Hématologie seniors
FRANCA
NOUVELLE AQUITAINE
PESSAC
EPAG 2015 : A phase II randomized placebo-controlled study to assess the impact on outcome of Eltrombopag administered to elderly patients with acute myeloid leukemia receiving induction chemotherapy
CHU de Bordeaux-GH Sud - Hôpital Haut-Lévêque
Service d'hématologie et thérapie cellulaire
FRANCA
OCCITANIE
TOULOUSE
A Phase 1/2, Multicenter, Dose-Escalating Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy Of Quizartinib Administered in Combination with Re-Induction Chemotherapy, and as a Single-Agent Maintenance Therapy, in Pediatric Relapsed/Refractory AML Subjects Aged 1 Month to <18 Years (and Young Adults Aged up to 21 Years) with FLT3-ITD mutations - FR
CHU de Toulouse - Hôpital des Enfants
Hôpital des enfants
FRANCA
PROVENCE-ALPES-COTE D'AZUR
MARSEILLE
Etude Phase I/II d'immunothérapie Par protéine recWT1-A10+AS01B après Greffe allogénique de Cellules Souches (Phase I-II) - FR
CLCC Institut Paoli Calmettes
Institut Paoli-Calmettes
FRANCA
PROVENCE-ALPES-COTE D'AZUR
MARSEILLE
Prospective and Multicentre Evaluation of 3 Different Doses of IV Busulfan Associated With Fludarabine and Thymoglobuline in the Conditioning of Allogeneic Stem Cell Transplantation (SCT) From a Matched Related or Unrelated Donor in Patients With Poor Prognosis Myeloid Malignancies (Phase II) - FR
CLCC Institut Paoli Calmettes
Institut Paoli-Calmettes
ITALIA
FRIULI VENEZIA GIULIA
UDINE
Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML)
Azienda Ospedaliero-Universitaria "Santa Maria della Misericordia" di Udine
Clinica Ematologica
ITALIA
LAZIO
ROMA
Study protocol for acute myeloid leukemia in children and adolescent
IRCCS Ospedale Pediatrico Bambino Gesù - SEDE GIANICOLO
U.O. di Onco-Ematologia
ITALIA
LAZIO
ROMA
Clofarabine in combination with standard remission induction regimen (AraC and idarubicin) in patients 20-60 years old with previously untreated intermediate and bad risk acute myelogenous leukemia (AML)
Sapienza Università di Roma - Dipartimento di Neurologia e Psichiatria
Dipartimento di Biotecnologie Cellulari ed Ematologia
ITALIA
LOMBARDIA
MILANO
Multicenter Phase II Study of Haploidentical Hematopoietic Cell Transplantation With CD3/CD19 Depleted Grafts After a Reduced Intensity Conditioning Regimen for Adult Patients With Acute Leukemia
IRCCS Ospedale San Raffaele
Dipartimento di Ematologia
NORUEGA
Vestlandet
BERGEN
A Phase II Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia - NO -
Haukeland University Hospital
PAISES BAIXOS
Gelderland
NIJMEGEN
Clofarabine in Combination With a Standard Remission Induction Regimen (AraC and Idarubicin) in Patients 18-60 Years Old With Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS) : a Phase I-II Study of the EORTC-LG and GIMEMA (AML-14A Trial)
Radboudumc - Radboud universitair medisch centrum
Afdeling Hematologie
PAISES BAIXOS
Zuid-Holland
LEIDEN
Clofarabine in combination with a standard remission induction regimen (AraC and idarubicin) in patients 18-60 years old with previously untreated intermediate and bad risk acute myelogenous leukemia (AML) or high risk myelodysplasia (MDS): a phase I-II study of the EORTC-LG and GIMEMA (AML-14A trial)
LUMC - Leids Universitair Medisch Centrum
Afdeling Hematologie
PAISES BAIXOS
Zuid-Holland
LEIDEN
Prophylactic infusion of CD4 positive donor lymphocytes early after T-cell depleted allogeneic stem cell transplantation in patients with an unrelated donor (phase II)
LUMC - Leids Universitair Medisch Centrum
Afdeling Hematologie
POLONIA
Lodz
LODZ
Evaluation of the Efficacy of Induction-consolidation Treatment Using a Double Induction in Patients With AML <60 Years Old, Depending on the Percentage of Blasts in the 14 Day, Residual Disease and Leukemic Hematopoietic Cells
Wojewodzki Szpital Specjalistyczny im. M. Kopernika w Lodzi
Oddzial Hematologii
REINO UNIDO
Devon
EXETER
WT1 Immunity via DNA fusion Gene Vaccination in Haematological Malignancies by intramuscular injection followed by intramuscular electroporation - WIN: Anti-WT1 DNA fusion gene vaccine in haematological malignancies
Royal Devon and Exeter Hospital - Wonford site
Department of Haematology
REINO UNIDO
Essex
HARLOW
ASPIRE: A three-part, phase II study of Eltrombopag in thrombocytopenic subjects with Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: open-label, part 2: randomized, double-blind, part 3: extension) - DE
GlaxoSmithKline Research & Development Ltd.
GlaxoSmithKline Research & Development Limited
REINO UNIDO
Greater London
LONDON
CaspaCide TCR α β haplo HSCT: Follow-up of Phase 1/2 Study of CaspaCIDe T Cells (BPX-501) From an HLA-partially Matched Family Donor After Negative Selection of TCR α β+T Cells in Pediatric Patients Affected by Hematological Disorders-GB
GOSH NHS Foundatin Trust
Great Ormond Street Hospital
REINO UNIDO
Greater London
LONDON
UK Haplo v1.0: A UK multicentre phase II study of haploidentical stem cell transplantation in patients with haematological malignancies
Guy's Hospital
Department of Haematology
REINO UNIDO
Greater London
LONDON
An Exploratory, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of ATIR, Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy, Who Received a CD34-selected Hematopoietic Stem Cell Transplantation From a Haploidentical Donor - GB
Hammersmith Hospital
Hammersmith Hospital Haemophilia Centre
REINO UNIDO
Greater London
LONDON
WT1 Immunity via DNA fusion Gene Vaccination in Haematological Malignancies by intramuscular injection followed by intramuscular electroporation - WIN: Anti-WT1 DNA fusion gene vaccine in haematological malignancies
Imperial College NHS Trust
REINO UNIDO
Greater London
UXBRIDGE
REINO UNIDO
Hampshire
SOUTHAMPTON
A Pilot Study of Clofarabine Pre-Conditioning Prior to Full or Reduced Intensity Allogeneic Transplantation in the Treatment of High Risk Acute Myeloid Leukaemia and Myelodysplasia - Clofarabine pre-conditioning with allogeneic transplant for AML
Southampton General Hospital
University Hospitals Southampton NHS Foundation Trust
REINO UNIDO
Hampshire
SOUTHAMPTON
WT1 Immunity via DNA fusion Gene Vaccination in Haematological Malignancies by intramuscular injection followed by intramuscular electroporation - WIN: Anti-WT1 DNA fusion gene vaccine in haematological malignancies
University of Southampton
School of Medicine (Medical Oncology)
REINO UNIDO
Nottinghamshire
NOTTINGHAM
A Phase 2, Randomized, Open-Label Study of the Safety and Efficacy of Two Doses of Quizartinib (AC220; ASP2689) in Subjects with FLT3-ITD Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) - UK
LAM Action Nottingham, Voluntary Action Centre
Nottingham Haematology Group
REINO UNIDO
South Glamorgan
CARDIFF
AML 16: A Programme of Treatment Development for Older Patients With Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome (PhaseII/III)
Cardiff University School of Medicine
Department of Medical Genetics, Haematology & Pathology
REINO UNIDO
South Glamorgan
CARDIFF
AML 17: Randomised, controlled, open label, multi-arm trial looking at treatment for acute promyelocytic leukaemia (Phase III)
Cardiff University School of Medicine
Department of Medical Genetics, Haematology & Pathology
REINO UNIDO
West Midlands
BIRMINGHAM
FIGARO - A Randomised Trial of the FLAMSA-BU Conditioning Regimen in Patients with Acute Myeloid Leukaemia and Myelodysplasia Undergoing Allogeneic Stem Cell Transplantation
Queen Elizabeth Hospital
CRUK Clinical Trials Unit
REINO UNIDO
West Midlands
BIRMINGHAM
RAvVA: Phase II Randomised Trial of 5-Azacitidine versus 5-Azacitidine in combination with Vorinostat in patients with Relapsed Acute Myeloid Leukaemia ineligible for Intensive Chemotherapy
Queen Elizabeth Hospital
CRUK Clinical Trials Unit
REINO UNIDO
West Midlands
BIRMINGHAM
REINO UNIDO
West Midlands
BIRMINGHAM
REINO UNIDO
West Midlands
BIRMINGHAM
PARC: Phase I/II Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100) in Relapsed/Refractory Cancers of Children and Young Adults -GB
University of Birmingham
University of Birmingham HQ
REINO UNIDO
Greater London
LONDON
An open-label, uncontrolled, multicenter, multinational study on the efficacy and safety of administration of donor lymphocytes depleted of alloreactive T-cells (ATIR), through the use of TH9402 and light treatment in an ex vivo process, in patients receiving a CD34-selected peripheral blood stem cell graft from a related, haploidentical donor (Phase II/III) - UK
Faculty of Medicine - Imperial College of London
Centre for Haematology
BELGICA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
STEP: Sorafenib Long Term Extension Program - BE
Cliniques universitaires Saint-Luc - UCLouvain
Pneumologie_Oncologie thoracique
Ensaio (s) clínico (s) multinacional (ais)
ALEMANHA
Hamburg
HAMBURG
HaploMUD: Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia With Identical GVHD Prophylaxis - A Randomized Prospective European Trial
UKE - Universitätsklinikum Hamburg-Eppendorf
Interdisziplinäre Klinik und Poliklinik für Stammzelltransplantation
ALEMANHA
Sachsen
LEIPZIG
BERGAMO: A Phase II Study Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes Failing Standard of Care Therapy
Universitätsklinikum Leipzig AöR
Klinik und Poliklinik für Hämatologie, Zelltherapie und Hämostaseologie
AUSTRALIA
Victoria
RICHMOND
Phase III Clinical Study of Allogeneic Stem CellTransplantation with Reduced Conditioning (RICT)versus Best Standard of Care in Acute Myeloid Leukemia(AML) in First Complete Remission
Australasian Leukaemia & Lymphoma Group (ALLG)
ESTADOS UNIDOS
California
SAN DIEGO
Phase 2 Open-Label, AC220 Monotherapy Efficacy (ACE) Study in Patients With Acute Myeloid Leukemia (AML) With FLT3-ITD Activating Mutations (coordination)
Ambit Biosciences Corporation
ESTADOS UNIDOS
Massachusetts
CAMBRIDGE
AGILE: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination With Azacitidine in Subjects ≥ 18 Years of Age With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
Agios Pharmaceuticals, Inc.
ESTADOS UNIDOS
New Jersey
EDISON
ESTADOS UNIDOS
New Jersey
RARITAN
Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) (Phase III) (coordination)
Johnson & Johnson
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
ESTADOS UNIDOS
Texas
HOUSTON
CaspaCide TCR α β haplo HSCT: Follow-up of Phase 1/2 Study of CaspaCIDe T Cells (BPX-501) From an HLA-partially Matched Family Donor After Negative Selection of TCR α β+T Cells in Pediatric Patients Affected by Hematological Disorders
Bellicum Pharmaceuticals, Inc.
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
Phase 1b, Multi-arm, Open-label Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Institution: Information not provided - US
NORUEGA
Østlandet
OSLO
PAISES BAIXOS
Noord-Holland
AMSTERDAM
SAIL: An Investigator-Initiated Study To Evaluate Ara-C and Idarubicin in Combination with the Selective Inhibitor Of Nuclear Export (SINE) Selinexor (KPT-330) in Patients with Relapsed Or Refractory AML
GSO Global Clinical Research B.V.
SUECIA
Region Stockholm
ADDRESS: NOT PROVIDED - SE
SPARK-AML1: A Randomised, Open-label, Multi-centre, 2-stage, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC) in Comparison With LDAC Alone in Patients Aged > 60 With Newly Diagnosed Acute Myeloid Leukaemia (AML) (Phase II) (coordination)
Institution: Information not provided - SE
ESPANHA
Madrid
COLMENAR VIEJO